Semaglutide vs. Tirzepatide: How to Compare Your Options
Compare semaglutide and tirzepatide, including the head-to-head trial, product differences, safety questions, and practical trade-offs.
On this page
The short answer
Semaglutide acts on the GLP-1 receptor, while tirzepatide acts on both GIP and GLP-1 receptors. Tirzepatide produced greater average weight loss in a major head-to-head trial, but the right choice also depends on your health, the exact product, side effects, and ongoing access.
Compare the actual products first
Semaglutide and tirzepatide are ingredient names. Before comparing an offer, find out which product, formulation, and care plan those names refer to. For a broader introduction, start with our GLP-1 guide.
| Feature | Semaglutide | Tirzepatide |
|---|---|---|
| Receptors targeted | GLP-1 | GIP and GLP-1 |
| Weight-management brand discussed here | Wegovy | Zepbound |
| Current brand formulations | Wegovy injections and tablets | Zepbound injections |
| Practical question | “Which formulation are you recommending?” | “Which injection presentation will I receive?” |
These product details come from the current prescribing information. The comparison below focuses on a trial of weekly injections, not tablets. 1 2
Do not compare two program cards by ingredient name alone. Ask for a written answer if the website does not clearly identify the medication.
What did the head-to-head trial show?
SURMOUNT-5 randomized 751 adults with obesity, without type 2 diabetes, to tirzepatide or semaglutide injections for 72 weeks. Estimated average weight reduction was 20.2% with tirzepatide and 13.7% with semaglutide. Trial maintenance doses were the maximum tolerated of 10 or 15 mg for tirzepatide and 1.7 or 2.4 mg for semaglutide. These describe study conditions, not instructions for your prescription. It was an open-label study funded by Eli Lilly, tirzepatide’s manufacturer. 3
That is useful comparative evidence. It is not a forecast for an individual, and it does not establish the same outcomes for every dose, oral formulation, or compounded preparation. The study also reported gastrointestinal side effects in both groups, mainly mild to moderate and often during dose escalation. 3
When a provider quotes a percentage, ask: “Which study is that from, which product did participants receive, and how closely does it match the treatment you are offering me?”
You do not need to be able to interpret a full research paper to expect a clear answer. A percentage should come with enough context to understand what it describes.
Which differences matter for your decision?
Put the study result alongside the questions that affect your actual care:
| Decision | What to discuss |
|---|---|
| Health fit | Why this option is appropriate for your diagnoses, history, and goals |
| Tolerability | How the clinician will respond if symptoms interfere with eating or daily activities |
| Product | The exact brand or compounded preparation and how it is supplied |
| Routine | The instructions you would need to follow and any practical difficulties |
| Affordability | The total ongoing payment, including care and supplies |
| Continuity | What happens if coverage, availability, or your circumstances change |
It can help to choose two priorities before your appointment. For example: “I want a clear explanation of the evidence, and I need to understand what I will pay after the first month.” This keeps the discussion focused without choosing the prescription for the clinician.
Safety questions deserve their own conversation
Both product labels contraindicate use with a personal or family history of medullary thyroid carcinoma or MEN2, and with specified serious hypersensitivity. Both contain important warnings beyond common digestive symptoms. Have your clinician review the relevant medication guide with you. 1 2
Tirzepatide has a specific precaution for oral hormonal contraception: the Zepbound label advises a non-oral method or an added barrier method for four weeks after starting and four weeks after each dose increase. Arrange that discussion before treatment if it applies to you. 2
Bring a complete medication list, even if you have taken the same prescriptions for years. Add a separate question about pregnancy plans, breastfeeding, or an upcoming procedure when relevant. Our eligibility guide helps organize that history, and our side-effects article explains when to seek help.
What changes when an offer is compounded?
Compounded preparations are not FDA-approved generic versions of Wegovy or Zepbound. They have not gone through FDA’s premarket assessment as finished products. 4
If a provider recommends one, ask why that preparation is medically appropriate for you and what an approved alternative would involve. Do not assume that a brand-name trial establishes the safety, quality, or effectiveness of the preparation being offered. See compounded versus brand-name GLP-1 medicines.
Bring this comparison note to your appointment
Copy these prompts and fill them in during the discussion:
- Recommended product: What exactly would I receive?
- Reason: Why does this option fit my health history?
- Alternative: What is the other reasonable option, and why might we choose it?
- Follow-up: When will we review how I am doing?
- Contact: Who should I speak with about side effects or confusing instructions?
- Total cost: What will I pay now and on renewal?
If an answer is unclear, ask the clinician to explain it in different words. You should leave understanding the plan, not just remembering which drug “won” a comparison.
Common questions
Does greater average weight loss make tirzepatide better for everyone?
No. The trial answers a defined research question in a defined group. Your decision still requires a clinical assessment and a practical plan for using the prescribed product.
Can I convert one dose into the other?
Do not work out a switch from an online conversion table or your remaining supply. Ask the prescribing clinician for product-specific instructions before changing treatment.
How should I compare prices?
Compare the same billing period and list what is included. A first-month offer is not enough to understand ongoing cost. Use our GLP-1 cost guide to compare the full plan, then review Ēlovi’s published plans.
References
- Wegovy Prescribing Information — Novo Nordisk
- Zepbound Prescribing Information — Eli Lilly and Company
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity — New England Journal of Medicine; abstract indexed by PubMed
- Compounding and the FDA: Questions and Answers — U.S. Food and Drug Administration
For your information. This article provides general education and does not replace medical advice or an individual evaluation. Talk to your clinician before starting, changing, or stopping treatment. Compounded medications are not FDA-approved.